ArticleMolecular pharmacology2018
Protective Effect of a Locked Retinal Chromophore Analog against Light-Induced Retinal Degeneration.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Inhibition of galanin receptor 3 slows down retina degeneration in retinitis pigmentosa through modulation of inflammatory and oxidative stress response.Scientific reports · 2026Article
- Therapeutic Potential of Partial Retinoid Agonists against Vertebrate Rhodopsin Misfolding Disorders.ACS omega · 2025Article
- Retinoid dynamics in vision: from visual cycle biology to retina disease treatments.Pharmacology & therapeutics · 2025Review
- Advances and therapeutic opportunities in visual cycle modulation.Progress in retinal and eye research · 2025Review
- Mechanisms of Rhodopsin-Related Inherited Retinal Degeneration and Pharmacological Treatment Strategies.Cells · 2025Review
- Discovery of non-retinoid compounds that suppress the pathogenic effects of misfolded rhodopsin in a mouse model of retinitis pigmentosa.PLoS biology · 2025Article
- Light as a Mediator of Acute and Chronic Retina Degeneration.Advances in experimental medicine and biology · 2025Review
- Development of novel cytoprotective small compounds inhibiting mitochondria-dependent cell death.iScience · 2023Article
- Galanin receptor 3 - A new pharmacological target in retina degeneration.Pharmacological research · 2023Article
- Chromenone derivatives as novel pharmacological chaperones for retinitis pigmentosa-linked rod opsin mutants.Human molecular genetics · 2022Article
- Mice Lacking the Systemic Vitamin A Receptor RBPR2 Show Decreased Ocular Retinoids and Loss of Visual Function.Nutrients · 2022Article
- Flavonoids improve the stability and function of P23H rhodopsin slowing down the progression of retinitis pigmentosa in mice.Journal of neuroscience research · 2022Article
- The vitamin A transporter STRA6 adjusts the stoichiometry of chromophore and opsins in visual pigment synthesis and recycling.Human molecular genetics · 2022Article
- Polyphenols and Visual Health: Potential Effects on Degenerative Retinal Diseases.Molecules (Basel, Switzerland) · 2021Review
- Protective Effects of Flavonoids in Acute Models of Light-Induced Retinal Degeneration.Molecular pharmacology · 2021Article
- Retinoid analogs and polyphenols as potential therapeutics for age-related macular degeneration.Experimental biology and medicine (Maywood, N.J.) · 2020Review
- The Retinoid and Non-Retinoid Ligands of the Rod Visual G Protein-Coupled Receptor.International journal of molecular sciences · 2019Review
- Flavonoids enhance rod opsin stability, folding, and self-association by directly binding to ligand-free opsin and modulating its conformation.The Journal of biological chemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Songqi GaoDepartment of Pharmacology, School of Medicine (S.G., T.P., M.G., K.P., B.J.) and Cleveland Center for Membrane and Structural Biology (M.G., K.P., B.J.), Case Western Reserve University, and Polgenix Inc., Department of Medical Devices (G.P., Z.D.), Cleveland, Ohio.
Tanu ParmarDepartment of Pharmacology, School of Medicine (S.G., T.P., M.G., K.P., B.J.) and Cleveland Center for Membrane and Structural Biology (M.G., K.P., B.J.), Case Western Reserve University, and Polgenix Inc., Department of Medical Devices (G.P., Z.D.), Cleveland, Ohio.
Grazyna PalczewskaDepartment of Pharmacology, School of Medicine (S.G., T.P., M.G., K.P., B.J.) and Cleveland Center for Membrane and Structural Biology (M.G., K.P., B.J.), Case Western Reserve University, and Polgenix Inc., Department of Medical Devices (G.P., Z.D.), Cleveland, Ohio.
Zhiqian DongDepartment of Pharmacology, School of Medicine (S.G., T.P., M.G., K.P., B.J.) and Cleveland Center for Membrane and Structural Biology (M.G., K.P., B.J.), Case Western Reserve University, and Polgenix Inc., Department of Medical Devices (G.P., Z.D.), Cleveland, Ohio.
Marcin GolczakDepartment of Pharmacology, School of Medicine (S.G., T.P., M.G., K.P., B.J.) and Cleveland Center for Membrane and Structural Biology (M.G., K.P., B.J.), Case Western Reserve University, and Polgenix Inc., Department of Medical Devices (G.P., Z.D.), Cleveland, Ohio.
Krzysztof PalczewskiDepartment of Pharmacology, School of Medicine (S.G., T.P., M.G., K.P., B.J.) and Cleveland Center for Membrane and Structural Biology (M.G., K.P., B.J.), Case Western Reserve University, and Polgenix Inc., Department of Medical Devices (G.P., Z.D.), Cleveland, Ohio bxj27@case.edu kxp65@case.edu.
Beata JastrzebskaDepartment of Pharmacology, School of Medicine (S.G., T.P., M.G., K.P., B.J.) and Cleveland Center for Membrane and Structural Biology (M.G., K.P., B.J.), Case Western Reserve University, and Polgenix Inc., Department of Medical Devices (G.P., Z.D.), Cleveland, Ohio bxj27@case.edu kxp65@case.edu.
Case Western Reserve University · US
Funding
TISSUE CULTURE AND HYBRIDOMA MODULEP30EY011373 · NEI · CASE WESTERN RESERVE UNIVERSITY · PI Irina A Pikuleva · 1997 to 2026
$17.7MSTRUCTURAL STUDIES OF ARRESTINSR01EY009339 · NEI · UNIVERSITY OF WASHINGTON · PI KISER, PHILIP DAVID, PALCZEWSKI, KRZYSZTOF · 1992 to 2025
$16.0MNovel therapies to inhibit Diabetic RetinopathyR24EY024864 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI KERN, TIMOTHY S · 2015 to 2019
$8.1MUse of systems pharmacology to prevent rod and cone photoreceptor degenerationR24EY027283 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI PALCZEWSKI, KRZYSZTOF · 2017 to 2021
$7.9MRegulation of vitamin A metabolism in the eyeR01EY023948 · NEI · CASE WESTERN RESERVE UNIVERSITY · PI GOLCZAK, MARCIN BERNARD · 2014 to 2023
$3.8MA two-photon ophthalmoscope for human retinal imaging and functional testingU01EY025451 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI PALCZEWSKI, KRZYSZTOF · 2015 to 2019
$3.2MNon-hydrolysable analogs of retinal chromophore; potential new therapeutics to prevent retinal degenerationR01EY025214 · NEI · CASE WESTERN RESERVE UNIVERSITY · PI JASTRZEBSKA, BEATA · 2016 to 2020
$1.8MNEI NIH HHS P30 EY011373NEI NIH HHS R01 EY009339NEI NIH HHS R01 EY023948NEI NIH HHS R01 EY025214NEI NIH HHS R24 EY024864NEI NIH HHS R24 EY027283NEI NIH HHS U01 EY025451
Abstract
Continuous regeneration of the 11-
Indexed as
Alcohol OxidoreductasesAnimalsATP-Binding Cassette TransportersDiterpenesLightMacular DegenerationMiceMice, Inbred BALB CMice, Inbred C57BLOpsinsProtective AgentsRetinaRetinal DegenerationRetinaldehydeRetinoids9-cis-retinalAlcohol OxidoreductasesATP-Binding Cassette TransportersDiterpenesOpsinsProtective AgentsRetinaldehydeRetinoids
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.